2025 - Proof of principle2025 is about proof of principle for PGX from first Health Canada approval for the first PGX product(immune booster) and first commercial sales on a small scale(50L). Scale-up to the decision point for mass industrialization with Natex(100L) is also expected in Q1,
The avenanthramide pill could also reslease its first data in humans from safety/tolerability, to preliminary efficacy from its Phase I/IIa clinical trial. We've yet to see any data whether preclinical or clinical for the pill as the company guards important knowledge at this early stage.
These are key strategic milestones for the company.
This was a better speculation when the stock was priced for a stable, growing, profitable base business and the interesting pipeline with multiple shots on goal was free. Unfortunatly the lead client for the base business was spun-out and its demand changed. Now one has to be right about the pipeline which is hard to judge at this stage as the company also loses money and is secretive. Do they have anything? Canadian pharma icon Ronnie Miller was attracted to the pipeline and the credible new director recently added suggests a story. Gilles joined the company because of avenanthramide which has an interesting and large peer-reviewed published data base and the pill will have data from safety, to tolerability, to preliminary efficacy in 2025. Dr. Li is a very credible player in the scientific field and stayed with this company. The company has the preliminary exercise inflammation data and Dr. Li was very hot on the preclinical wound healing data however the company has been quiet. The company is using the global opinion leader Dr. Tardif to manage its clinical trial. Other scientists have suggested the potential of avenanthramide in yeast beta glucan capsules with published research. PGX yeast beta glucan impregnated with avenanthramide could be a novel and compelling product but there is work to do. We have yet to see data for CSCI's pill as the company guards the opportunity. The limitation for avenenthramide has been production at scale and CSCI has increased scale 4X and has some potential clients reviewing the opportunity for food applications. The credibility of the new President and CEO will help tell the story. It typically takes 3-6 months to hire a new President and CEO so we could hear about the new one at any time from now through Q1. The yeast beta glucan immune booster has been successfully scaled-up to 50L and the product is being finalized for Health Canada approval and commercial launch in Q1 and Q2. PGX scale-up to 100L is expected to be completed in Q1 with NATEX.This is the decision point for mass industrialization of PGX.Does CSCI have the emerging yeast beta glucan gold standard in the industry with significant new characteristics with its first Health Canada approved product able to be sold for the first time at small commercial scale? Health Canada approval, first commercial pruduct at small scale, decision point for mass industrialization are key market events. It could be interesting at this stage and a new President and CEO could tell the story with a proof of principle in place for global production.There is also the launch of the chewable products lines and we await more into.